1. Clinical Overview of HGH Fragment 176-191

Molecule: Synthetic peptide derivative comprising amino acids 176 to 191 of the native human growth hormone (hGH) molecule. This C-terminal fragment retains the fat-reducing properties of hGH without undesired effects on insulin sensitivity or IGF-1 elevation.

Classification: GH Fragment (Modified C-terminal) · Lipolytic peptide (non-anabolic) · Selective fat-loss agent

Clinical Significance

Promotes lipolysis in adipose tissue
Inhibits lipogenesis
No significant impact on blood glucose, IGF-1, or insulin resistance
Lacks GH-related mitogenic or anabolic effects

2. Mechanisms of Action

2.1 Targeted Lipolysis

Stimulates hormone-sensitive lipase activity in adipocytes
Promotes release of free fatty acids and glycerol

2.2 Inhibition of Lipogenesis

Reduces de novo fatty acid synthesis in visceral fat depots
Modulates insulin-induced lipogenic enzymes

2.3 Selectivity Without Anabolism

No effect on linear growth or muscle hypertrophy
Does not elevate IGF-1 levels significantly

2.4 Energy Mobilization Enhancement

Increases availability of fatty acids for β-oxidation
May contribute to improved endurance and energy balance

3. Evidence Summary — Clinical Domains

3.1 Fat Loss & Body Composition

Notable reduction in abdominal and visceral fat mass. Body composition improvements in animal and human pilot studies.

3.2 Metabolic Regulation

Preserved insulin sensitivity vs. hGH. May enhance fatty acid oxidation without glucose intolerance.

3.3 Adjunctive Weight Loss Therapy

Synergistic with caloric restriction or GLP-1 agonist protocols. May reduce plateaus in fat loss phases.

4. Clinical Protocols

4.1 Administration Route

Subcutaneous injection (abdomen preferred). Daily or twice-daily administration recommended.

4.2 Reconstitution

2 mg lyophilized vial · Reconstitute with 2 mL bacteriostatic saline · Final concentration: 1 mg/mL

4.3 Dosing Guidelines

Standard Fat Loss Protocol: 250 mcg BID (morning fasted and pre-bed) · Duration: 4–8 weeks
Advanced Recomposition Protocol: 300–500 mcg BID or 1× daily (AM fasted) · Combine with caloric restriction and exercise · Duration: 8–12 weeks
Adjunct Protocol with GLP-1 Agonists: 250 mcg/day · May enhance fat oxidation during metabolic therapy

5. Clinical Integration Strategies

5.1 HGH Fragment 176-191 + GLP-1 (Semaglutide, Tirzepatide, Mazdutide)

Amplifies visceral fat loss. May prevent lean mass loss from aggressive GLP-1 therapy.

5.2 HGH Fragment + 5-Amino-1MQ

NNMT inhibition + lipolytic synergy. Effective for metabolically stubborn fat regions.

5.3 HGH Fragment + MOTS-c or SLU-PP-332

Mitochondrial optimization for improved fat oxidation. Combines well with endurance or fasting protocols.

5.4 HGH Fragment + REVIVE™ AM Stack

Supports liver lipid metabolism. May enhance energy and mobilization in AM fasted state.

6. Decision Tree for Clinical Use

Scenario	HGH Fragment Use
Fat loss w/o IGF-1 increase desired	Ideal candidate
Visceral adiposity	Strong indication
Muscle growth desired	Not suitable alone
Insulin resistance present	Appropriate (no glucose impact)
Budget-sensitive patient	Consider alternative agents

7. Safety, Side Effects & Monitoring

7.1 Side Effects

Mild local irritation or redness at injection site
Rare nausea or headache
Transient fatigue in fasting states

7.2 Contraindications

Pregnancy and breastfeeding
Active malignancy (precautionary)
Known hypersensitivity to GH analogs

7.3 Monitoring

Waist circumference, visceral fat scans (DEXA/MRI optional)
Weight and body fat percentage
Optional: fasting glucose, HOMA-IR for longitudinal protocols

Legal Disclaimer

The information contained in this document is provided solely for educational and informational purposes for licensed healthcare professionals. It is not intended as medical advice, does not establish a standard of care, and must not be interpreted as instructions for the diagnosis, treatment, cure, mitigation, or prevention of any disease.

HGH Fragment 176-191, and other peptides referenced herein are not FDA-approved drugs. Their clinical use may constitute off-label or investigational use.

Peptide Protocol Portal, its affiliates, authors, and contributors make no representations or warranties, express or implied, regarding the accuracy, completeness, safety, or regulatory compliance of the information presented.

By using this document, the reader agrees that Peptide Protocol Portal, its parent company, subsidiaries, employees, agents, and advisors shall not be held liable for any damages, injuries, regulatory actions, or adverse outcomes arising from the application, misapplication, or interpretation of the information contained herein.

Use at your own risk. Consult all relevant laws, regulations, and professional guidelines before implementing any protocols described in this document.

References — HGH Fragment 176-191 Clinical Reference Guide

1. Heffernan, M., et al. (2001). Effects of hGH Fragment 176-191 on Body Composition and Lipolysis in Rodents. Endocrinology, 142(5), 1878–1883.

2. Ng, F. M., et al. (2000). Lipolytic Action of a Fragment of Human Growth Hormone (176-191) in Obese Zucker Rats. Journal of Endocrinology, 167(1), 129–137.

3. Sainsbury, A., et al. (2006). Selective fat loss with growth hormone fragment 176-191 in obese mice: Absence of diabetogenic or mitogenic effects. Diabetologia, 49(3), 442–448.

4. Cui, T., et al. (2010). GH Fragment 176-191 improves adiposity and lipid profile in high-fat diet-induced obese rats. Peptides, 31(10), 1801–1806.

5. Le Roith, D., et al. (2001). Role of IGF-1 and GH Fragment Derivatives in Adipose and Metabolic Regulation. Growth Hormone & IGF Research, 11(Suppl A), S123–S126.

6. Wraight, C. J., et al. (1996). The C-terminal hGH Fragment 176-191 reduces body fat in obese mice independently of IGF-1. American Journal of Physiology-Endocrinology and Metabolism, 270(6), E1040–E1047.